Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BOSTON SCIENTIFIC CORPBSX · Entity 1897 | EVP Pres MedSurg | February 28, 2022 | March 02, 2022 |
| DIVERSIFIED HEALTHCARE TRUSTNASDAQ:DHC · Entity 4565 | Director | June 05, 2023 | June 06, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BOSTON SCIENTIFIC CORP
Report date February 28, 2022 · Filed March 02, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2022-03-01 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2022-02-28 · Exercise / conversion · Acquired 2,444 · Balance 2,444 F1: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Row 2 · 2022-02-28 · Tax withholding · Disposed 718 · Balance 1,726 Row 3 · 2022-03-01 · Sale · Disposed 1,726 · Balance 0 F2: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. |
| Deferred Stock UnitsSEC Table II · derivative / convertible security · Expires 2022-02-28 | Direct | 0 |
Reported balance
After 2022-02-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-02-28 · Exercise / conversion · Disposed 2,444 · Balance 0 F1: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
F2: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.
F3: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant.
DIVERSIFIED HEALTHCARE TRUST
Report date June 05, 2023 · Filed June 06, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares of Beneficial InterestSEC Table I · non-derivative | Direct | 40,000 |
Reported balance
After 2023-06-05 transaction · row 1
1 source rowRow 1 · 2023-06-05 · Grant · Acquired 20,000 · Balance 40,000 F1: Transaction reported is grant of shares pursuant to the Issuer's equity compensation plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction reported is grant of shares pursuant to the Issuer's equity compensation plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2023 Filed Jun 6, 2023 22:04 UTC | DIVERSIFIED HEALTHCARE TRUST NASDAQ:DHC · Entity 4565 | GrantCommon Shares of Beneficial Interest | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-068604 · tm2317817-2_4seq1.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 F1 · price: Transaction reported is grant of shares pursuant to the Issuer's equity compensation plan. Read SEC document |
| June 02, 2022 Filed Jun 4, 2022 01:14 UTC | DIVERSIFIED HEALTHCARE TRUST NASDAQ:DHC · Entity 4565 | GrantCommon Shares of Beneficial Interest | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-068223 · tm2217479-3_4seq1.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · price: Transaction reported is grant of shares pursuant to the Issuer's equity compensation plan. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 21:29 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 1,726 | $43.94 | $75,840.44 |
DisclosureSEC source: 0001225208-22-003867 · doc4.xml · nonDerivative · entry 3 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:29 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003867 · doc4.xml · derivative · entry 4 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,444 shares Expires 2022-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:29 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 718 | $44.17 | $31,714.06 |
DisclosureSEC source: 0001225208-22-003867 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,726 Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:29 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003867 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 23, 2022 Filed Feb 24, 2022 21:21 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 1,761 | $43.28 | $76,216.08 |
DisclosureSEC source: 0001225208-22-003299 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:21 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantPerformance Share Units · Derivative | 17,439 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003299 · doc4.xml · derivative · entry 3 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,439 Underlying: Common Stock · 17,439 shares Expires 2023-12-31 F2 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · shares: On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2023. F3 · derivative.exercise_date: On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2023. F3 · derivative.expiration_date: On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2023. F3 · balance_after: On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2023. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:21 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 1,884 | $42.55 | $80,164.20 |
DisclosureSEC source: 0001225208-22-003299 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,761 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| February 21, 2022 Filed Feb 23, 2022 21:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,493 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003087 · doc4.xml · derivative · entry 3 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,493 Underlying: Common Stock · 2,493 shares Expires 2023-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2022 Filed Feb 23, 2022 21:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 732 | $42.55 | $31,146.60 |
DisclosureSEC source: 0001225208-22-003087 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,645 Read SEC document |
| February 21, 2022 Filed Feb 23, 2022 21:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,493 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003087 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,377 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 21:46 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,668 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002932 · doc4.xml · derivative · entry 7 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,337 Underlying: Common Stock · 2,668 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 21:46 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 2,354 | $42.88 | $100,939.52 |
DisclosureSEC source: 0001225208-22-002932 · doc4.xml · nonDerivative · entry 5 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,884 F3 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-l trading plan. Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 21:46 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 784 | $42.55 | $33,359.20 |
DisclosureSEC source: 0001225208-22-002932 · doc4.xml · nonDerivative · entry 4 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,238 Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 21:46 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,668 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002932 · doc4.xml · nonDerivative · entry 3 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,022 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:46 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 3,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002932 · doc4.xml · derivative · entry 6 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 3,333 shares Expires 2025-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:46 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 979 | $42.83 | $41,930.57 |
DisclosureSEC source: 0001225208-22-002932 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,354 Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:46 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 3,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002932 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 01:34 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 1,956 | $43.81 | $85,692.36 |
DisclosureSEC source: 0001225208-22-002694 · doc4.xml · nonDerivative · entry 3 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-l trading plan. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:34 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,769 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002694 · doc4.xml · derivative · entry 4 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,769 Underlying: Common Stock · 2,769 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:34 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 813 | $44.01 | $35,780.13 |
DisclosureSEC source: 0001225208-22-002694 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,956 Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:34 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,769 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002694 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,769 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 21:32 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 6,161 | $43.54 | $268,229.61 |
DisclosureSEC source: 0001225208-22-000470 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $43.23 to $43.79, inclusive. The reporting person undertakes to provide upon request by the U.S.Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 01, 2022 Filed Jan 3, 2022 21:53 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionPerformance Share Units · Derivative | 8,982 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-000116 · doc4.xml · derivative · entry 3 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,982 shares Expires 2021-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F1 · shares: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021. F1 · derivative.exercise_date: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021. F1 · derivative.expiration_date: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021. Read SEC document |
| January 01, 2022 Filed Jan 3, 2022 21:53 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 2,821 | $42.48 | $119,836.08 |
DisclosureSEC source: 0001225208-22-000116 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,161 Read SEC document |
| January 01, 2022 Filed Jan 3, 2022 21:53 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 8,982 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-000116 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,982 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021. Read SEC document |
| December 20, 2021 Filed Dec 21, 2021 21:33 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 42,934 | $0.00 Strike: $7.39 | $0.00 |
DisclosureSEC source: 0001225208-21-015180 · doc4.xml · derivative · entry 5 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,934 shares Expires 2023-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant. Read SEC document |
| December 20, 2021 Filed Dec 21, 2021 21:33 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,997 | $0.00 Strike: $6.28 | $0.00 |
DisclosureSEC source: 0001225208-21-015180 · doc4.xml · derivative · entry 4 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,997 shares Expires 2022-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. Read SEC document |
| December 20, 2021 Filed Dec 21, 2021 21:33 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 49,988 | $39.90 | $1,994,621.18 |
DisclosureSEC source: 0001225208-21-015180 · doc4.xml · nonDerivative · entry 3 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $39.47 to $40.31, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 20, 2021 Filed Dec 21, 2021 21:33 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 4,997 | $6.28 | $31,381.16 |
DisclosureSEC source: 0001225208-21-015180 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,988 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| December 20, 2021 Filed Dec 21, 2021 21:33 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 42,934 | $7.39 | $317,282.26 |
DisclosureSEC source: 0001225208-21-015180 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,991 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 20:07 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 1,654 | $41.36 | $68,409.44 |
DisclosureSEC source: 0001225208-21-009034 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,057 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 20:20 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,973 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-008789 · doc4.xml · derivative · entry 3 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,973 shares Expires 2021-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on June 1, 2017, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on June 1, 2017, the first anniversary of the date of grant. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 20:20 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,319 | $42.93 | $56,624.67 |
DisclosureSEC source: 0001225208-21-008789 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,711 Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 20:20 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,973 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-008789 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,030 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| March 16, 2021 Filed Mar 17, 2021 20:08 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 7,603 | $39.36 | $299,245.72 |
DisclosureSEC source: 0001225208-21-005427 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,057 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $39.295 to $39.51, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 21:07 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 1,360 | $38.90 | $52,904.00 |
DisclosureSEC source: 0001225208-21-004699 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,660 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-004226 · doc4.xml · derivative · entry 3 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,444 Underlying: Common Stock · 2,444 shares Expires 2022-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,084 | $38.78 | $42,037.52 |
DisclosureSEC source: 0001225208-21-004226 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,020 Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-004226 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,104 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 23, 2021 Filed Feb 24, 2021 21:07 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 2,836 | $39.20 | $111,171.20 |
DisclosureSEC source: 0001225208-21-003606 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,660 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 22:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantPerformance Share Units · Derivative | 9,456 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003526 · doc4.xml · derivative · entry 8 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,456 Underlying: Common Stock · 9,456 shares Expires 2022-12-31 F5 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F6 · shares: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2022. F6 · derivative.exercise_date: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2022. F6 · derivative.expiration_date: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2022. F6 · balance_after: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2022. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 22:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,607 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003526 · doc4.xml · derivative · entry 7 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,607 shares Expires 2021-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 22:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,157 | $39.20 | $45,354.40 |
DisclosureSEC source: 0001225208-21-003526 · doc4.xml · nonDerivative · entry 5 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,496 Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 22:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,607 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003526 · doc4.xml · nonDerivative · entry 4 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,653 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 21, 2021 Filed Feb 23, 2021 22:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 2,492 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003526 · doc4.xml · derivative · entry 6 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,986 Underlying: Common Stock · 2,492 shares Expires 2023-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2021 Filed Feb 23, 2021 22:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,106 | $38.03 | $42,061.18 |
DisclosureSEC source: 0001225208-21-003526 · doc4.xml · nonDerivative · entry 3 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,046 Read SEC document |
| February 21, 2021 Filed Feb 23, 2021 22:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,492 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003526 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,152 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 22:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 1,484 | $38.00 | $56,392.00 |
DisclosureSEC source: 0001225208-21-003526 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,660 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.